Skip to main content
Glama

Cbioportal

by io.github.pipeworx-io

Entity Profile

entity_profile
Read-onlyIdempotent

"Tell me about X" / "research Acme" / "brief me on Tesla" / "what does Apple do" / "company profile for Microsoft" / "give me the rundown on NVDA" / "everything you know about $TICKER" — full cross-source profile of a US public company in ONE parallel call. ALWAYS PREFER over chaining single-pack SEC/XBRL/news lookups when the user asks for a holistic view. Fans out across SEC EDGAR, XBRL, USPTO patents, federal contracts (USAspending), FDA-licensed biologics (Purple Book), H-1B hiring (DOL LCA), news and GLEIF, and returns: cik + company_name (+ resolved_from/resolved_to when value was a name); recent_filings (up to 5 with pipeworx://edgar/company/{cik}/filings/{accession} URIs); fundamentals (LATEST 10-K Revenues + NetIncomeLoss + Cash, sorted period_end DESC); patents (USPTO PatentsView API sunset May 2025 — soft-fails until reactivated); federal_contracts (USAspending awards where the company is the recipient); fda_products (FDA-licensed biologics — vaccines, cell/gene therapies — from the Purple Book; a company with only small-molecule/generic drugs will show none here, that is expected, not a failure); hiring (H-1B sponsorship volume + salary range from DOL LCA filings); recent news mentions via GDELT→GNews fallback; LEI via GLEIF. sources_used / sources_failed say which of these actually returned data for THIS company — an empty section is a real "no data", not a bug. Pass a ticker ("AAPL"), zero-padded CIK ("0000320193"), OR a company name ("Moderna") — names now resolve via SEC EDGAR's company-name match; a private company (no CIK/ticker) returns resolved:false with an explicit notes line, not a bare failure. type accepts "company" or "ticker" interchangeably — both take the same value shapes above.

Input Schema

TableJSON Schema
NameRequiredDescriptionDefault
typeYes"company" or "ticker" — both are accepted and behave identically; `value` can be a ticker, CIK, or company name either way. person/place coming soon.
valueYesTicker (e.g., "AAPL"), zero-padded CIK (e.g., "0000320193"), or company name (e.g., "Moderna") — names resolve via SEC EDGAR company-name match.

TDQS

A4.8/5.0
Behavior5/5

Does the description disclose side effects, auth requirements, rate limits, or destructive behavior?

Beyond the readOnly/idempotent/openWorld annotations, the description discloses fan-out behavior, the sources_used/sources_failed mechanism, that an empty section means real no-data rather than a bug, and that private companies return resolved:false with a notes line instead of a bare failure. No contradiction with annotations.

Agents need to know what a tool does to the world before calling it. Descriptions should go beyond structured annotations to explain consequences.

Conciseness4/5

Is the description appropriately sized, front-loaded, and free of redundancy?

The description is long but dense, with trigger phrases front-loaded and the core one-call profile behavior stated early. The later source/return enumeration and edge-case notes are arguably necessary given there is no output schema, though the sentence structure is heavy with nested clauses.

Shorter descriptions cost fewer tokens and are easier for agents to parse. Every sentence should earn its place.

Completeness5/5

Given the tool's complexity, does the description cover enough for an agent to succeed on first attempt?

With no output schema, the description compensates by listing the main return fields (cik, company_name, recent_filings, fundamentals, patents, federal contracts, FDA products, hiring, news, LEI) and the sources_used/sources_failed status fields. It also covers resolution semantics, accepted inputs, and the private-company edge case, so an agent has enough context to call it correctly.

Complex tools with many parameters or behaviors need more documentation. Simple tools need less. This dimension scales expectations accordingly.

Parameters4/5

Does the description clarify parameter syntax, constraints, interactions, or defaults beyond what the schema provides?

The input schema already covers both parameters at 100%, and the description adds extra value by clarifying that 'type' accepts 'company' or 'ticker' interchangeably, giving real examples, and explaining name resolution via SEC EDGAR and private-company behavior. This goes beyond the baseline 3 for high schema coverage.

Input schemas describe structure but not intent. Descriptions should explain non-obvious parameter relationships and valid value ranges.

Purpose5/5

Does the description clearly state what the tool does and how it differs from similar tools?

The description opens with concrete user intents ('Tell me about X', 'research Acme', 'brief me on Tesla') and then defines the exact action: 'full cross-source profile of a US public company in ONE parallel call.' It enumerates the sources fanned out (SEC EDGAR, XBRL, USPTO, etc.), which distinguishes this aggregated profile tool from single-lookup siblings.

Agents choose between tools based on descriptions. A clear purpose with a specific verb and resource helps agents select the right tool.

Usage Guidelines5/5

Does the description explain when to use this tool, when not to, or what alternatives exist?

It explicitly tells the agent when to prefer this tool: 'ALWAYS PREFER over chaining single-pack SEC/XBRL/news lookups when the user asks for a holistic view.' It also covers input variants (ticker, zero-padded CIK, company name) and the private-company fallback, giving clear boundary conditions.

Agents often have multiple tools that could apply. Explicit usage guidance like "use X instead of Y when Z" prevents misuse.

All Cbioportal toolsInspect
Try in Browser
RayrunBuild, deploy, and operate MCP servers without becoming an infrastructure team.ray.runAd

Glama MCP Gateway

Add one secure layer between your agents and this server.

TDQS

A3.6/5.0
Disambiguation3/5

Most tools have clearly distinct purposes, but ask_pipeworx_beta is an intentional near-duplicate of ask_pipeworx, and several polymarket/entity tools overlap in scope. The descriptions do enough to disambiguate most pairs, but the duplicate beta routing tool introduces real ambiguity.

Naming Consistency3/5

All names use snake_case, but the pattern varies: verb_noun (get_gene, search_studies), noun_noun (polymarket_edges, pipeworx_trending), and product-prefixed verbs (ask_pipeworx, bet_research). There is no single consistent convention, though the names remain readable.

Tool Count2/5

35 tools is a heavy surface, and the vast majority (31) are unrelated to cBioPortal; only four tools actually belong to the named domain. This makes the count inappropriate for a cancer-genomics MCP server, as the set is bloated with out-of-scope utilities.

Completeness1/5

For a cBioPortal server, only metadata-level tools exist (gene lookup, study details, cancer types, study search); core cBioPortal data access — mutations, copy-number alterations, clinical data, molecular profiles, sample-level queries — is entirely missing. The tool surface severely under-covers the named domain.

Resources